Insulet shared new data on its insulin pumps for people with Type 2 diabetes at the American Diabetes Association’s Scientific Sessions this weekend. The insulin pump manufacturer received an expanded indication from the Food and Drug Administration in August, allowing people with Type 2 diabetes to use its Omnipod 5 automated insulin delivery system, which takes readings from a glucose sensor to adjust insulin doses from a pump.
Eric Benjamin, Insulet’s chief product and customer experience officer, said in an interview that the share of new patients with Type 2 diabetes has increased since receiving the expanded indication. More than 30% of new patient starts in the first quarter of 2025 were people with Type 2 diabetes, according to Benjamin. Insulet has not provided future estimates.
“The human impact has been tremendous,” Benjamin said, adding that the company is seeing more interest from providers, and that insurance coverage has been “really good” for both Type 1 and Type 2 users. All of Insulet’s patch pumps are sold through the pharmacy channel.
At the ADA conference, Insulet presented a new analysis of its SECURE-T2D pivotal trial, which was used to gain the expanded indication last year. The analysis found that Insulet’s Omnipod 5 AID system reduced users’ diabetes distress over 13 weeks, based on a questionnaire that asks people about worries regarding low blood sugar and long-term health, challenges in accessing care and how they manage the daily demands of diabetes. The single-arm study enrolled 305 people and was funded by Insulet.
Plans for future AID systems
Insulet named longtime medtech executive Ashley McEvoy as CEO in April to take the company into the next phase of growth. Insulet is developing new AID systems, including a next generation hybrid closed loop system, where users still provide some input, as well as a fully closed loop system, where all insulin dosing would be automated.
Insulet started enrolling in March for its STRIVE study to test the new hybrid closed loop system, former CEO Jim Hollingshead told investors in a February earnings call. The new system will include a lower set point for blood glucose levels, more personalization and other quality of life benefits, Benjamin said. Insulet has not provided timing on the next data readout.
Insulet is also working on a closed-loop system for people with Type 2 diabetes. The company plans to begin its second set of EVOLUTION studies for that program in the second half of this year, according to Benjamin.
With hybrid closed loop systems, users may still interact with an AID system to calculate mealtime insulin doses, flag exercise and make manual adjustments. A fully closed loop system is “the closest you can get to technology performing the functions of a working pancreas,” Benjamin said.
The company is focusing on Type 2 diabetes to start because the risk of hypoglycemia is lower than in people with Type 1 diabetes.
“The most salient thing we learned in the first set of studies is that we can do this in a reasonable timeline for people with Type 2 diabetes,” Benjamin added.
He expects that faster-acting insulins will be needed to make fully automated systems for Type 1 diabetes.
Competitors including Tandem, Medtronic and Beta Bionics are developing their own patch pumps, to which Benjamin said “imitation is the finest form of flattery.”
He expects Insulet to keep its position as the market leader by continuing to innovate and ensuring its technology is the most accessible.
